MLTX (STOCKS)
MoonLake Immunotherapeutics Class A Ordinary Shares
$19.100000
+0.410000 (+2.19%)
Prev close: $18.690000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jorge Santos da Silva
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,413.05M
- Employees
- 100
- P/E (TTM)
- -4.96
- P/B (TTM)
- 5.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
10
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.98 | $-0.91 | -0.0703 | -7.73% |
|
Dec 2025 (Q4)
|
$-0.92 | $-1.01 | +0.0911 | +9.03% |
|
Sep 2025 (Q3)
|
$-1.10 | $-0.90 | -0.2039 | -22.75% |
|
Jun 2025 (Q2)
|
$-0.87 | $-0.74 | -0.1343 | -18.25% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $267.37M |
| Research and Development | $220.92M |
| Other Operating Expenses | $46.46M |
| Operating Income/Loss | -$267.37M |
| Income/Loss From Continuing Operations After Tax | -$259.47M |
| Income/Loss From Continuing Operations Before Tax | -$258.49M |
| Income Tax Expense/Benefit | $1.08M |
| Net Income/Loss | -$259.47M |
| Net Income/Loss Attributable To Noncontrolling Interest | -$2.39M |
| Net Income/Loss Attributable To Parent | -$257.08M |
| Net Income/Loss Available To Common Stockholders, Basic | -$257.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.87 |
| Diluted Earnings Per Share | -$3.87 |
| Basic Average Shares | 199,094,252 |
| Diluted Average Shares | 199,094,252 |
| Assets | $400.37M |
| Current Assets | $396.64M |
| Cash | $357.90M |
| Prepaid Expenses | $32.96M |
| Other Current Assets | $5.78M |
| Noncurrent Assets | $3.73M |
| Fixed Assets | $532.00K |
| Other Non-current Assets | $3.20M |
| Liabilities | $146.35M |
| Current Liabilities | $46.11M |
| Wages | $2.20M |
| Other Current Liabilities | $43.92M |
| Noncurrent Liabilities | $100.24M |
| Long-term Debt | $99.02M |
| Other Non-current Liabilities | $1.22M |
| Equity | $254.02M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $254.02M |
| Liabilities And Equity | $400.37M |
| Net Cash Flow From Operating Activities | -$224.15M |
| Net Cash Flow From Operating Activities, Continuing | -$224.15M |
| Net Cash Flow From Investing Activities | $146.84M |
| Net Cash Flow From Investing Activities, Continuing | $146.84M |
| Net Cash Flow From Financing Activities | $103.52M |
| Net Cash Flow From Financing Activities, Continuing | $103.52M |
| Net Cash Flow | $26.21M |
| Net Cash Flow, Continuing | $26.21M |
| Comprehensive Income/Loss | -$261.57M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | -$2.42M |
| Comprehensive Income/Loss Attributable To Parent | -$259.16M |
| Other Comprehensive Income/Loss | -$2.10M |